CBC Group, Asia's largest healthcare-dedicated investment firm, is committed to creating value and integrating global resources. Partnering with the world's top entrepreneurs and scientists, its unique investor-operator approach has empowered global leading healthcare companies to widen access to affordable medical care, catalyze innovations, and improve efficiency in fulfilling unmet medical needs worldwide.
Founded in 2014, CBC has a leading team of investment, industry and portfolio management professionals headquartered in Singapore with offices in Shanghai, Beijing, Hong Kong and New York, and presences in Boston, San Diego, San Francisco, and Tokyo. CBC focuses on platform-building, buyout, credit and growth-focused opportunities across multiple core areas within the healthcare sector, including pharmaceutical and biotech, medical technology and healthcare services.
Matrix Partners China
Founded in 2008, Matrix Partners China is one of the leading venture capital firms focused on early stage and early growth deals in China, now managing over 50 billion RMB.
Matrix Partners China mainly invests in new economy, deep technology, industrial digitalization, healthcare, frontier technology and new consumer brands. The firm has invested in more than 700 companies. Matrix Partners China has over 40 investment professionals with deep sector knowledge. The firm also established one of the largest portfolio management teams in the market. Over 100 professionals formed 10 different functions including strategy and operation consulting, recruiting, and healthcare services, etc., to provide value added services to entrepreneurs.
Established in 2003, Beijing Konruns Pharmaceutical Co., Ltd. adheres to its core mission of "Our Life Science Cares Your Health". Over sixteen years, Konruns Pharmaceutical has developed into a high-tech pharmaceutical company that integrates R&D, production, and marketing by pursuing new drug research and development, and focusing on new special drugs.
Konruns Pharmaceutical was listed on the Shanghai Stock Exchange (Stock Code: 603590) in August 2018.
Focus on innovative medicine, RTW Investments have developed expertise through comprehensive study of industry and academic efforts in targeted areas of significant innovation.
By focusing our energies, we believe we can add more value to entrepreneurs and scientists. Our current focus areas include both technology platforms and disease areas.
HBM Healthcare Investments
HBM Healthcare Investments is a Swiss investment company holding a well-balanced globally diversified portfolio of investments in private and public healthcare companies.
HBM Healthcare Investments invests primarily in more mature private companies with an attractive valuation and a convincing business model including product pipeline, technology and management.
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
If successfully developed and approved, Verona Pharma's product candidate, Ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound.
Aerogen Pharma is an Irish specialty pharmaceutical company developing inhaled products for quick, efficient, consistent and user-friendly treatment of critically ill patients in hospital acute care. Aerogen Pharma improves existing drugs by targeting them to the lung using a proprietary, high performance aerosol delivery system based on the market-leading nebulizer technology created by its parent organization, the Aerogen group.
Nuance Pharma Announces Clearance of IND Application for Respiratory Syncytial Virus (RSV) Vaccine in China
SHANGHAI, Nov. 13, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces the Center for Drug Evaluation ("CDE") has approved its Investigational New Drug ("IND") application supporting its pivotal phase III clinical tr
优锐医药首席运营官陈晨 对话蔻德 - 新浪《蕊智会》
中国的创新药改革历程中，license in是一个绕不开的话题。在众多关注肿瘤与免疫项目license in的公司中，专注于呼吸领域精品特药以及贫血和镇痛的优锐医药显得格外独特。
Nuance Pharma announces Ensifentrine China IND Approval
August 16th, 2022, Nuance Pharma announces IND approval from the Center for Drug Evaluation (CDE) for supporting its pivotal clinical trials of Ensifentrine in the treatment of chronic obstructive pulmonary disease (COPD) in China.